is diarrhea a symptom of glp 1 on GLP-1 common, predictable, and manageable. Here's what's driving it and what to do about it. #obesitymedicine #womenshealth #obesitydoctor​​​​​​​​​​​​​​​​ The potential for complex interplay

Bristol-Myers Squibb (BMS) Total Revenue: $48.19B Founded Year: 1887 Total Employees: 32,500 Headquarters: New Jersey, United States Market Cap: $121.42B Stock Exchange: NYSE BMS is a global biopharma company focused on oncology, hematology, immunology, and cardiovascular diseases, with a strong portfolio of innovative therapies and a legacy of blockbuster drugs

That said, nausea is most commonly reported for semaglutide and least commonly reported for dulaglutide

While albiglutide demonstrated good glycemic efficacy and tolerability, adverse effects included upper respiratory tract infections, diarrhea, nausea, and injection site reactions

In practice combination therapies can deliver stronger glycemic control, more noticeable weight reduction, and a better patient response than using a single medication on its own, even when the goal seems the same

Future Prescr

Increasing demand for obesity treatment therapies The growing demand for obesity treatment therapies is turning into a pretty big driver of growth in the global GLP-1 agonists market